J B Chemicals & Pharmaceuticals Ltd · JBCHEPHARM · Pharma - Formulators · prices and results as of 16 July 2026, updated weekly · research updated 17 May 2026
J B Chemicals & Pharmaceuticals share price: ₹2,408.90 at the close on 16 July 2026, the latest close in our records; up 45.6% in the year to that date. J B Chemicals & Pharmaceuticals (JBCHEPHARM) is worth ₹38,677 crore, trades at a P/E of 53.2 and has closed between ₹1,654.10 and ₹2,435.50 over the past 52 weeks. Latest change: profit fell in the March 2026 quarter.
J B Chemicals & Pharmaceuticals Ltd's share price has risen faster than its earnings: +45.6% in a year, against +6.6% for earnings per share.
The main question: the share price moved +45.6% in a year while earnings per share (last four quarters) moved +6.6%. The difference came from the market paying a higher multiple.
The price has been rising for 34 weeks, and the P/E is higher than 98% of its own last 10 years. Over the last four quarters, results have been deteriorating, with profit −30.8% on a year earlier, and 125% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.
What is the J B Chemicals & Pharmaceuticals share price?
J B Chemicals & Pharmaceuticals Ltd's share price was ₹2,408.90 at the close on 16 July 2026. It has been rising for 34 weeks. That is 18.9% above its average price over the last 200 trading days.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today J B Chemicals & Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.
In the last 52 weeks it traded between ₹1,654 and ₹2,436, and at that close it sat 97% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 9 weeks in a row.
Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 321 of 536 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 26 Feb 2016 | no NIFTY 500 reading |
| 4 Mar 2016 | no NIFTY 500 reading |
| 11 Mar 2016 | no NIFTY 500 reading |
| 18 Mar 2016 | no NIFTY 500 reading |
| 23 Mar 2016 | no NIFTY 500 reading |
| 1 Apr 2016 | no NIFTY 500 reading |
| 8 Apr 2016 | no NIFTY 500 reading |
| 13 Apr 2016 | no NIFTY 500 reading |
| 22 Apr 2016 | no NIFTY 500 reading |
| 29 Apr 2016 | no NIFTY 500 reading |
| 6 May 2016 | no NIFTY 500 reading |
| 13 May 2016 | no NIFTY 500 reading |
| 20 May 2016 | no NIFTY 500 reading |
| 27 May 2016 | −12.6% |
| 3 Jun 2016 | −16.1% |
| 10 Jun 2016 | −15.8% |
| 17 Jun 2016 | −10.6% |
| 24 Jun 2016 | −12.0% |
| 1 Jul 2016 | −9.3% |
| 8 Jul 2016 | −6.9% |
| 15 Jul 2016 | −4.1% |
| 22 Jul 2016 | +0.1% |
| 29 Jul 2016 | −1.9% |
| 5 Aug 2016 | +3.1% |
| 12 Aug 2016 | −2.5% |
| 19 Aug 2016 | −5.8% |
| 26 Aug 2016 | +23.9% |
| 2 Sep 2016 | +17.2% |
| 9 Sep 2016 | +33.1% |
| 16 Sep 2016 | +49.3% |
| 23 Sep 2016 | +44.9% |
| 30 Sep 2016 | +37.1% |
| 7 Oct 2016 | +31.8% |
| 14 Oct 2016 | +45.3% |
| 21 Oct 2016 | +38.6% |
| 30 Oct 2016 | +41.9% |
| 4 Nov 2016 | +26.0% |
| 11 Nov 2016 | +31.7% |
| 18 Nov 2016 | +31.4% |
| 25 Nov 2016 | +8.2% |
| 2 Dec 2016 | +18.2% |
| 9 Dec 2016 | +5.7% |
| 16 Dec 2016 | −4.2% |
| 23 Dec 2016 | −1.6% |
| 30 Dec 2016 | +4.3% |
| 6 Jan 2017 | +3.2% |
| 13 Jan 2017 | −8.4% |
| 20 Jan 2017 | −5.3% |
| 27 Jan 2017 | −10.8% |
| 3 Feb 2017 | −3.5% |
| 10 Feb 2017 | −15.2% |
| 17 Feb 2017 | −14.5% |
| 23 Feb 2017 | −15.3% |
| 3 Mar 2017 | −17.1% |
| 10 Mar 2017 | −14.9% |
| 17 Mar 2017 | −18.7% |
| 24 Mar 2017 | −12.5% |
| 31 Mar 2017 | −16.0% |
| 7 Apr 2017 | −12.8% |
| 13 Apr 2017 | −14.7% |
| 21 Apr 2017 | −14.7% |
| 28 Apr 2017 | −14.1% |
| 5 May 2017 | −15.3% |
| 12 May 2017 | −7.9% |
| 19 May 2017 | −5.4% |
| 26 May 2017 | −7.3% |
| 2 Jun 2017 | −8.1% |
| 9 Jun 2017 | −5.9% |
| 16 Jun 2017 | −1.5% |
| 23 Jun 2017 | −6.7% |
| 30 Jun 2017 | −13.9% |
| 7 Jul 2017 | −13.6% |
| 14 Jul 2017 | −11.0% |
| 21 Jul 2017 | −11.6% |
| 28 Jul 2017 | −11.4% |
| 4 Aug 2017 | −14.6% |
| 11 Aug 2017 | −13.7% |
| 18 Aug 2017 | −19.3% |
| 24 Aug 2017 | −18.0% |
| 1 Sep 2017 | −20.7% |
| 8 Sep 2017 | −21.3% |
| 15 Sep 2017 | −21.7% |
| 22 Sep 2017 | −21.1% |
| 29 Sep 2017 | −14.0% |
| 6 Oct 2017 | −15.8% |
| 13 Oct 2017 | −17.6% |
| 19 Oct 2017 | −18.3% |
| 27 Oct 2017 | −13.3% |
| 3 Nov 2017 | −6.8% |
| 10 Nov 2017 | −7.0% |
| 17 Nov 2017 | −7.4% |
| 24 Nov 2017 | −5.8% |
| 1 Dec 2017 | +0.9% |
| 8 Dec 2017 | +2.2% |
| 15 Dec 2017 | −0.4% |
| 22 Dec 2017 | +6.3% |
| 29 Dec 2017 | +10.2% |
| 5 Jan 2018 | +7.1% |
| 12 Jan 2018 | +13.1% |
| 19 Jan 2018 | +10.8% |
| 25 Jan 2018 | +3.4% |
| 2 Feb 2018 | −0.6% |
| 9 Feb 2018 | −0.7% |
| 16 Feb 2018 | +6.5% |
| 23 Feb 2018 | +5.6% |
| 1 Mar 2018 | +9.1% |
| 9 Mar 2018 | +2.9% |
| 16 Mar 2018 | +2.3% |
| 23 Mar 2018 | −3.0% |
| 28 Mar 2018 | −1.7% |
| 6 Apr 2018 | −2.0% |
| 13 Apr 2018 | −2.5% |
| 20 Apr 2018 | +0.6% |
| 27 Apr 2018 | +5.2% |
| 4 May 2018 | +7.0% |
| 11 May 2018 | +4.7% |
| 18 May 2018 | +2.9% |
| 25 May 2018 | −3.7% |
| 1 Jun 2018 | −15.6% |
| 8 Jun 2018 | −14.0% |
| 15 Jun 2018 | −7.1% |
| 22 Jun 2018 | −12.7% |
| 29 Jun 2018 | −19.7% |
| 6 Jul 2018 | −19.9% |
| 13 Jul 2018 | −19.8% |
| 20 Jul 2018 | −15.2% |
| 27 Jul 2018 | −17.2% |
| 3 Aug 2018 | −18.6% |
| 10 Aug 2018 | −9.9% |
| 17 Aug 2018 | −8.5% |
| 24 Aug 2018 | +5.5% |
| 31 Aug 2018 | +18.0% |
| 7 Sep 2018 | +21.6% |
| 14 Sep 2018 | +14.7% |
| 21 Sep 2018 | +8.5% |
| 28 Sep 2018 | +14.1% |
| 5 Oct 2018 | +22.5% |
| 12 Oct 2018 | +24.1% |
| 19 Oct 2018 | +21.6% |
| 26 Oct 2018 | +19.9% |
| 2 Nov 2018 | +20.6% |
| 9 Nov 2018 | +11.4% |
| 16 Nov 2018 | +8.1% |
| 22 Nov 2018 | +0.3% |
| 30 Nov 2018 | −3.6% |
| 7 Dec 2018 | −2.2% |
| 14 Dec 2018 | −5.1% |
| 21 Dec 2018 | +5.6% |
| 28 Dec 2018 | +2.1% |
| 4 Jan 2019 | +0.9% |
| 11 Jan 2019 | −3.5% |
| 18 Jan 2019 | −3.8% |
| 25 Jan 2019 | −1.1% |
| 1 Feb 2019 | −1.7% |
| 8 Feb 2019 | +5.0% |
| 15 Feb 2019 | +3.0% |
| 22 Feb 2019 | +10.2% |
| 1 Mar 2019 | +12.7% |
| 8 Mar 2019 | +7.7% |
| 15 Mar 2019 | +6.8% |
| 22 Mar 2019 | +7.7% |
| 29 Mar 2019 | +15.1% |
| 5 Apr 2019 | +8.6% |
| 12 Apr 2019 | +11.2% |
| 18 Apr 2019 | +5.3% |
| 26 Apr 2019 | +4.7% |
| 3 May 2019 | +5.1% |
| 10 May 2019 | −3.6% |
| 17 May 2019 | +1.6% |
| 24 May 2019 | +5.2% |
| 31 May 2019 | +3.8% |
| 7 Jun 2019 | +5.0% |
| 14 Jun 2019 | +11.2% |
| 21 Jun 2019 | +10.2% |
| 28 Jun 2019 | +1.3% |
| 5 Jul 2019 | +3.6% |
| 12 Jul 2019 | +8.9% |
| 19 Jul 2019 | +11.3% |
| 26 Jul 2019 | +12.2% |
| 2 Aug 2019 | +13.5% |
| 9 Aug 2019 | +17.1% |
| 16 Aug 2019 | +15.8% |
| 23 Aug 2019 | +9.0% |
| 30 Aug 2019 | +10.5% |
| 6 Sep 2019 | +10.1% |
| 13 Sep 2019 | +14.0% |
| 20 Sep 2019 | +9.3% |
| 27 Sep 2019 | −0.4% |
| 4 Oct 2019 | +6.9% |
| 11 Oct 2019 | −1.2% |
| 18 Oct 2019 | −3.1% |
| 27 Oct 2019 | −11.5% |
| 1 Nov 2019 | −14.2% |
| 8 Nov 2019 | −3.4% |
| 15 Nov 2019 | −2.1% |
| 22 Nov 2019 | −5.0% |
| 29 Nov 2019 | −5.9% |
| 6 Dec 2019 | −2.0% |
| 13 Dec 2019 | −4.3% |
| 20 Dec 2019 | −0.3% |
| 27 Dec 2019 | +15.2% |
| 3 Jan 2020 | +9.7% |
| 10 Jan 2020 | +14.0% |
| 17 Jan 2020 | +22.9% |
| 24 Jan 2020 | +39.8% |
| 1 Feb 2020 | +40.7% |
| 7 Feb 2020 | +42.6% |
| 14 Feb 2020 | +44.3% |
| 20 Feb 2020 | +32.8% |
| 28 Feb 2020 | +42.0% |
| 6 Mar 2020 | +51.3% |
| 13 Mar 2020 | +51.9% |
| 20 Mar 2020 | +47.3% |
| 27 Mar 2020 | +47.9% |
| 3 Apr 2020 | +35.1% |
| 9 Apr 2020 | +41.2% |
| 17 Apr 2020 | +37.7% |
| 24 Apr 2020 | +37.1% |
| 30 Apr 2020 | +32.0% |
| 8 May 2020 | +39.3% |
| 15 May 2020 | +33.3% |
| 22 May 2020 | +48.6% |
| 29 May 2020 | +41.9% |
| 5 Jun 2020 | +29.4% |
| 12 Jun 2020 | +21.7% |
| 19 Jun 2020 | +23.2% |
| 26 Jun 2020 | +11.1% |
| 3 Jul 2020 | +29.7% |
| 10 Jul 2020 | +21.6% |
| 17 Jul 2020 | +16.1% |
| 24 Jul 2020 | +10.8% |
| 31 Jul 2020 | +18.8% |
| 7 Aug 2020 | −8.2% |
| 14 Aug 2020 | −1.7% |
| 21 Aug 2020 | −7.8% |
| 28 Aug 2020 | −6.6% |
| 4 Sep 2020 | −2.1% |
| 11 Sep 2020 | +0.0% |
| 18 Sep 2020 | +44.5% |
| 25 Sep 2020 | +34.3% |
| 1 Oct 2020 | +29.1% |
| 9 Oct 2020 | +25.7% |
| 16 Oct 2020 | +38.7% |
| 23 Oct 2020 | +29.3% |
| 30 Oct 2020 | +31.3% |
| 6 Nov 2020 | +30.2% |
| 14 Nov 2020 | +13.3% |
| 20 Nov 2020 | +7.5% |
| 27 Nov 2020 | +13.8% |
| 4 Dec 2020 | +9.7% |
| 11 Dec 2020 | +6.7% |
| 18 Dec 2020 | −24.2% |
| 24 Dec 2020 | −15.9% |
| 1 Jan 2021 | −18.0% |
| 8 Jan 2021 | −15.6% |
| 15 Jan 2021 | −24.3% |
| 22 Jan 2021 | −21.8% |
| 29 Jan 2021 | −18.7% |
| 5 Feb 2021 | −23.6% |
| 12 Feb 2021 | +3.7% |
| 19 Feb 2021 | +0.6% |
| 26 Feb 2021 | −1.2% |
| 5 Mar 2021 | +6.4% |
| 12 Mar 2021 | +9.4% |
| 19 Mar 2021 | +2.8% |
| 26 Mar 2021 | +11.8% |
| 1 Apr 2021 | +13.2% |
| 9 Apr 2021 | +14.9% |
| 16 Apr 2021 | +13.9% |
| 23 Apr 2021 | +29.2% |
| 30 Apr 2021 | +30.0% |
| 7 May 2021 | +42.0% |
| 14 May 2021 | +15.6% |
| 21 May 2021 | +26.1% |
| 28 May 2021 | +20.2% |
| 4 Jun 2021 | +19.3% |
| 11 Jun 2021 | +18.5% |
| 18 Jun 2021 | +20.5% |
| 25 Jun 2021 | +17.6% |
| 2 Jul 2021 | +40.6% |
| 9 Jul 2021 | +36.6% |
| 16 Jul 2021 | +43.2% |
| 23 Jul 2021 | +26.0% |
| 30 Jul 2021 | +19.4% |
| 6 Aug 2021 | +12.9% |
| 13 Aug 2021 | +15.5% |
| 20 Aug 2021 | +12.7% |
| 27 Aug 2021 | +9.1% |
| 3 Sep 2021 | +1.3% |
| 9 Sep 2021 | +5.0% |
| 17 Sep 2021 | +1.4% |
| 24 Sep 2021 | +3.5% |
| 1 Oct 2021 | −10.0% |
| 8 Oct 2021 | −15.0% |
| 14 Oct 2021 | −19.6% |
| 22 Oct 2021 | −18.9% |
| 29 Oct 2021 | −17.9% |
| 4 Nov 2021 | −18.3% |
| 12 Nov 2021 | −17.3% |
| 18 Nov 2021 | −14.4% |
| 26 Nov 2021 | −4.7% |
| 3 Dec 2021 | −4.9% |
| 10 Dec 2021 | −9.6% |
| 17 Dec 2021 | −6.1% |
| 24 Dec 2021 | −4.9% |
| 31 Dec 2021 | −5.5% |
| 7 Jan 2022 | −7.5% |
| 14 Jan 2022 | −3.8% |
| 21 Jan 2022 | +5.2% |
| 28 Jan 2022 | +7.2% |
| 4 Feb 2022 | +8.1% |
| 11 Feb 2022 | +7.1% |
| 18 Feb 2022 | +1.5% |
| 25 Feb 2022 | −0.1% |
| 4 Mar 2022 | +4.1% |
| 11 Mar 2022 | +3.1% |
| 17 Mar 2022 | +0.4% |
| 25 Mar 2022 | −7.2% |
| 1 Apr 2022 | −13.1% |
| 8 Apr 2022 | −0.5% |
| 13 Apr 2022 | −3.2% |
| 22 Apr 2022 | −1.4% |
| 29 Apr 2022 | −2.7% |
| 6 May 2022 | −2.1% |
| 13 May 2022 | +2.9% |
| 20 May 2022 | +3.7% |
| 27 May 2022 | +3.4% |
| 3 Jun 2022 | −1.1% |
| 10 Jun 2022 | +2.9% |
| 17 Jun 2022 | +1.4% |
| 24 Jun 2022 | +8.9% |
| 1 Jul 2022 | +11.9% |
| 8 Jul 2022 | +5.8% |
| 15 Jul 2022 | +10.8% |
| 22 Jul 2022 | +5.1% |
| 29 Jul 2022 | +3.8% |
| 5 Aug 2022 | +9.5% |
| 12 Aug 2022 | +3.5% |
| 19 Aug 2022 | +3.0% |
| 26 Aug 2022 | +3.0% |
| 2 Sep 2022 | +5.6% |
| 9 Sep 2022 | +4.8% |
| 16 Sep 2022 | +14.7% |
| 23 Sep 2022 | +5.9% |
| 30 Sep 2022 | +11.8% |
| 7 Oct 2022 | +18.2% |
| 14 Oct 2022 | +10.6% |
| 21 Oct 2022 | +9.7% |
| 28 Oct 2022 | +3.1% |
| 4 Nov 2022 | +3.5% |
| 11 Nov 2022 | +4.5% |
| 18 Nov 2022 | +16.1% |
| 25 Nov 2022 | +9.4% |
| 2 Dec 2022 | +6.5% |
| 9 Dec 2022 | +8.7% |
| 16 Dec 2022 | +8.7% |
| 23 Dec 2022 | +5.7% |
| 30 Dec 2022 | −2.9% |
| 6 Jan 2023 | −3.9% |
| 13 Jan 2023 | −2.3% |
| 20 Jan 2023 | −4.2% |
| 27 Jan 2023 | +9.6% |
| 3 Feb 2023 | +6.8% |
| 10 Feb 2023 | +3.9% |
| 17 Feb 2023 | −3.9% |
| 24 Feb 2023 | +2.6% |
| 3 Mar 2023 | +4.9% |
| 10 Mar 2023 | +2.9% |
| 17 Mar 2023 | +0.4% |
| 24 Mar 2023 | +5.7% |
| 31 Mar 2023 | +7.4% |
| 6 Apr 2023 | +7.3% |
| 13 Apr 2023 | +13.2% |
| 21 Apr 2023 | +14.2% |
| 28 Apr 2023 | +2.5% |
| 5 May 2023 | −3.5% |
| 12 May 2023 | −0.4% |
| 19 May 2023 | −1.2% |
| 26 May 2023 | −2.4% |
| 2 Jun 2023 | +1.6% |
| 9 Jun 2023 | +1.9% |
| 16 Jun 2023 | +3.1% |
| 23 Jun 2023 | +5.3% |
| 30 Jun 2023 | +6.9% |
| 7 Jul 2023 | +0.9% |
| 14 Jul 2023 | +6.5% |
| 21 Jul 2023 | +3.2% |
| 28 Jul 2023 | +2.1% |
| 4 Aug 2023 | +19.7% |
| 11 Aug 2023 | +22.4% |
| 18 Aug 2023 | +25.4% |
| 25 Aug 2023 | +30.5% |
| 1 Sep 2023 | +24.0% |
| 8 Sep 2023 | +18.7% |
| 15 Sep 2023 | +21.8% |
| 22 Sep 2023 | +11.4% |
| 29 Sep 2023 | +20.0% |
| 6 Oct 2023 | +25.4% |
| 13 Oct 2023 | +9.6% |
| 20 Oct 2023 | +5.4% |
| 27 Oct 2023 | +13.8% |
| 3 Nov 2023 | +5.4% |
| 12 Nov 2023 | +9.6% |
| 17 Nov 2023 | +8.6% |
| 24 Nov 2023 | −4.9% |
| 1 Dec 2023 | −1.6% |
| 8 Dec 2023 | −2.5% |
| 15 Dec 2023 | −12.3% |
| 22 Dec 2023 | +7.1% |
| 29 Dec 2023 | −2.7% |
| 5 Jan 2024 | +0.2% |
| 12 Jan 2024 | +2.2% |
| 20 Jan 2024 | +6.2% |
| 25 Jan 2024 | +8.9% |
| 2 Feb 2024 | +3.2% |
| 9 Feb 2024 | −0.6% |
| 16 Feb 2024 | −5.4% |
| 23 Feb 2024 | +0.8% |
| 2 Mar 2024 | −6.9% |
| 7 Mar 2024 | +0.0% |
| 15 Mar 2024 | +5.6% |
| 22 Mar 2024 | −4.6% |
| 28 Mar 2024 | −2.7% |
| 5 Apr 2024 | −4.3% |
| 12 Apr 2024 | +1.8% |
| 19 Apr 2024 | +6.1% |
| 26 Apr 2024 | +2.5% |
| 3 May 2024 | +6.7% |
| 10 May 2024 | +2.8% |
| 18 May 2024 | +6.9% |
| 24 May 2024 | −4.5% |
| 31 May 2024 | +11.4% |
| 7 Jun 2024 | +6.8% |
| 14 Jun 2024 | +7.6% |
| 21 Jun 2024 | −3.2% |
| 28 Jun 2024 | −5.1% |
| 5 Jul 2024 | −9.4% |
| 12 Jul 2024 | −14.1% |
| 19 Jul 2024 | −11.5% |
| 26 Jul 2024 | −10.7% |
| 2 Aug 2024 | −9.0% |
| 9 Aug 2024 | −5.8% |
| 16 Aug 2024 | −2.8% |
| 23 Aug 2024 | +4.1% |
| 30 Aug 2024 | −2.2% |
| 6 Sep 2024 | −0.7% |
| 13 Sep 2024 | −4.0% |
| 20 Sep 2024 | −0.7% |
| 27 Sep 2024 | −3.8% |
| 4 Oct 2024 | −4.0% |
| 11 Oct 2024 | +1.0% |
| 18 Oct 2024 | +3.1% |
| 25 Oct 2024 | +3.8% |
| 1 Nov 2024 | +3.6% |
| 8 Nov 2024 | −3.4% |
| 14 Nov 2024 | −9.7% |
| 22 Nov 2024 | −2.5% |
| 29 Nov 2024 | −6.8% |
| 6 Dec 2024 | −7.8% |
| 13 Dec 2024 | −1.9% |
| 20 Dec 2024 | +7.5% |
| 27 Dec 2024 | +7.3% |
| 3 Jan 2025 | +12.4% |
| 10 Jan 2025 | +8.6% |
| 17 Jan 2025 | −0.1% |
| 24 Jan 2025 | −0.7% |
| 1 Feb 2025 | −3.8% |
| 7 Feb 2025 | −4.8% |
| 14 Feb 2025 | +5.3% |
| 21 Feb 2025 | −0.9% |
| 28 Feb 2025 | +7.1% |
| 7 Mar 2025 | +1.8% |
| 13 Mar 2025 | −3.9% |
| 21 Mar 2025 | −8.1% |
| 28 Mar 2025 | −5.8% |
| 4 Apr 2025 | −9.7% |
| 11 Apr 2025 | −9.0% |
| 17 Apr 2025 | −5.8% |
| 25 Apr 2025 | −14.1% |
| 2 May 2025 | −13.3% |
| 9 May 2025 | −8.9% |
| 16 May 2025 | −12.2% |
| 23 May 2025 | −4.2% |
| 30 May 2025 | −12.7% |
| 6 Jun 2025 | −5.5% |
| 13 Jun 2025 | +0.7% |
| 20 Jun 2025 | −0.9% |
| 27 Jun 2025 | +0.3% |
| 4 Jul 2025 | −6.1% |
| 11 Jul 2025 | −9.8% |
| 18 Jul 2025 | −6.9% |
| 25 Jul 2025 | +3.2% |
| 1 Aug 2025 | +7.2% |
| 8 Aug 2025 | +7.4% |
| 14 Aug 2025 | +5.1% |
| 22 Aug 2025 | +1.8% |
| 29 Aug 2025 | +4.4% |
| 5 Sep 2025 | +2.4% |
| 12 Sep 2025 | −3.2% |
| 19 Sep 2025 | −5.2% |
| 26 Sep 2025 | −3.4% |
| 3 Oct 2025 | +4.1% |
| 10 Oct 2025 | +3.8% |
| 17 Oct 2025 | +1.0% |
| 24 Oct 2025 | −3.3% |
| 31 Oct 2025 | −7.8% |
| 7 Nov 2025 | −4.1% |
| 14 Nov 2025 | +1.1% |
| 21 Nov 2025 | −4.5% |
| 28 Nov 2025 | −3.8% |
| 5 Dec 2025 | +1.8% |
| 12 Dec 2025 | +3.5% |
| 19 Dec 2025 | +4.5% |
| 26 Dec 2025 | +4.2% |
| 2 Jan 2026 | +6.3% |
| 9 Jan 2026 | +12.3% |
| 16 Jan 2026 | +12.9% |
| 23 Jan 2026 | +12.6% |
| 1 Feb 2026 | +14.2% |
| 6 Feb 2026 | +9.0% |
| 13 Feb 2026 | +6.0% |
| 20 Feb 2026 | +17.3% |
| 27 Feb 2026 | +19.1% |
| 6 Mar 2026 | +18.1% |
| 13 Mar 2026 | +27.9% |
| 20 Mar 2026 | +28.4% |
| 27 Mar 2026 | +24.7% |
| 2 Apr 2026 | +19.1% |
| 10 Apr 2026 | +11.0% |
| 17 Apr 2026 | +7.6% |
| 24 Apr 2026 | +9.3% |
| 30 Apr 2026 | +10.7% |
| 8 May 2026 | +17.6% |
| 15 May 2026 | +16.5% |
| 22 May 2026 | +12.8% |
| 29 May 2026 | +7.7% |
| 4 Jun 2026 | +4.0% |
| 5 Jun 2026 | −2.8% |
| 9 Jun 2026 | −2.6% |
| 10 Jun 2026 | −0.5% |
| 12 Jun 2026 | +7.2% |
| 17 Jun 2026 | +5.9% |
| 19 Jun 2026 | +8.6% |
| 24 Jun 2026 | +8.9% |
| 25 Jun 2026 | +7.9% |
| 1 Jul 2026 | +6.1% |
| 3 Jul 2026 | +7.1% |
| 10 Jul 2026 | +8.0% |
| 16 Jul 2026 | +8.1% |
Over the last 10 years the share price moved +1,854% while the NIFTY 500 moved +299%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at J B Chemicals & Pharmaceuticals this quarter?
Two changes stood out: profit fell in the March 2026 quarter and lowest operating margin in 12 quarters.
Profit fell in the March 2026 quarter
Profit was ₹101 crore, -30.8% on a year earlier (₹146 crore), after 9 quarters of growth.
Why: Profit fell because international sales dropped in the March quarter as shipments were held up by container congestion and inventory cuts.
Next results: check CDMO sales in the June quarter, since management said the problem is delivery execution, not customers or capacity.
From the earnings call on 12 May 2026.
Lowest operating margin in 12 quarters
Operating margin was 22% in the March 2026 quarter, against 24% a year earlier.
What are J B Chemicals & Pharmaceuticals' latest quarterly results?
For January to March 2026 (the quarter ended 31 March 2026), J B Chemicals & Pharmaceuticals reported revenue of ₹904 crore, down 4.7% from ₹949 crore a year earlier, and a profit of ₹101 crore, down 30.8% from ₹146 crore.
J B Chemicals & Pharmaceuticals results: January to March 2026 against a year earlier
| Measure | January to March 2026 | January to March 2025 | Change |
|---|---|---|---|
| Revenue | ₹904 crore | ₹949 crore | −4.7% |
| Profit | ₹101 crore | ₹146 crore | −30.8% |
| Earnings per share | ₹6.31 | ₹9.36 | −32.6% |
| Operating margin | 22.2% | 23.8% | −1.6 points |
The next results, for April to June 2026, are due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
J B Chemicals & Pharmaceuticals' management discussed these results on a call held on 12 May 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.
What is the J B Chemicals & Pharmaceuticals share price history?
J B Chemicals & Pharmaceuticals closed at ₹2,408.90 on 16 July 2026, up 45.6% from ₹1,654.10 a year earlier (18 July 2025) and up 154.6% over five years. Its highest weekly close since February 2016 was ₹2,435.50 on 10 July 2026.
J B Chemicals & Pharmaceuticals share price: then and now
| When | Close | Change to 16 Jul 2026 |
|---|---|---|
| 1 week ago · 10 Jul 2026 | ₹2,435.50 | −1.1% |
| 1 month ago · 17 Jun 2026 | ₹2,195.60 | +9.7% |
| 6 months ago · 16 Jan 2026 | ₹1,904.00 | +26.5% |
| 1 year ago · 18 Jul 2025 | ₹1,654.10 | +45.6% |
| 3 years ago · 14 Jul 2023 | ₹1,284.53 | +87.5% |
| 5 years ago · 16 Jul 2021 | ₹946.10 | +154.6% |
| 10 years ago · 15 Jul 2016 | ₹131.25 | +1,735.4% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹123.28 | +1,854.0% |
| Highest weekly close since February 2016, also the 52-week high · 10 Jul 2026 | ₹2,435.50 | −1.1% |
| Lowest weekly close since February 2016 · 24 Jun 2016 | ₹117.93 | +1,942.7% |
| 52-week low (weekly close) · 18 Jul 2025 | ₹1,654.10 | +45.6% |
Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 16 Jul 2026 close. A day's intraday high or low can go beyond these weekly closes.
549 weekly closes from 26 February 2016 to 16 July 2026.
What is the latest news on J B Chemicals & Pharmaceuticals?
16 Jul 2026: J B Chemicals & Pharmaceuticals closed at ₹2,408.90, down 1.1% on the week and up 9.7% on the month. 29 May 2026: ex-date for a dividend of ₹9.30 a share.
Earlier
- Our read, 17 May 2026: A chronic-mix compounder hit by a Torrent-integration reset, the branded core is intact, but CDMO missed by 12-14pp and management guidance credibility is impaired.
- 12 May 2026: J B Chemicals & Pharmaceuticals held its results call for January to March 2026. Management guided: India branded business return to double-digit or low-teens growth within couple of quarters.
- Results for January to March 2026: Revenue down 4.7% and profit down 30.8% on a year earlier.
- 11 Feb 2026: ex-date for an interim dividend of ₹12.70 a share.
Our read of the business
India branded grew 11% vs 10% IPM in FY26; chronic segment +19% vs industry +14%; 400 basis points gross margin expansion in Q4 to 70% from trade-generics exit, the underlying franchise is healthy.
January to March 2026: Integration reset complete; CDMO misses again by 12-14pp.
Our read after the January to March 2026 results, written 17 May 2026.
What dividend does J B Chemicals & Pharmaceuticals pay?
J B Chemicals & Pharmaceuticals paid ₹22 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 0.91% at the ₹2,408.90 close on 16 July 2026. The last was a dividend of ₹9.30 a share, ex-date 29 May 2026.
J B Chemicals & Pharmaceuticals dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 29 May 2026Dividend | ₹9.30 | Dividend | same day |
| 11 Feb 2026Interim | ₹12.70 | Interim | same day |
| 30 Jul 2025Dividend | ₹7 | Dividend | same day |
| 7 Feb 2025Interim | ₹8.50 | Interim | 8 Feb 2025 |
| 14 Aug 2024Dividend | ₹6.75 | Dividend | same day |
| 16 Feb 2024Interim | ₹5.50 | Interim | same day |
| 17 Aug 2023Dividend | ₹9.25 | Dividend | same day |
| 17 Feb 2023Interim | ₹8.50 | Interim | 18 Feb 2023 |
| 12 Aug 2022Dividend | ₹8 | Dividend | 17 Aug 2022 |
| 23 Feb 2022Interim | ₹8.50 | Interim | 24 Feb 2022 |
| 1 Sep 2021Dividend | ₹8 | Dividend | 2 Sep 2021 |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. J B Chemicals & Pharmaceuticals Ltd paid out 50% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What did J B Chemicals & Pharmaceuticals management say on the latest results call?
On the call for January to March 2026, held on 12 May 2026, J B Chemicals & Pharmaceuticals' management guided: India branded business return to double-digit or low-teens growth within couple of quarters.
“For the India business, double-digit growth or low-teens growth would take maybe a couple of quarters. We are already seeing all the positive signs.”Aman Mehta, MD, on the call for January to March 2026
What management guided
- International formulations single-digit growth trajectory expected from July to September 2026 onwards.
- CDMO business positive momentum on 12-month basis achievable if execution improves.
- Gross margin guidance deferred to April to June 2026 results for normalized run-rate clarity on cleaner trade-generics-free portfolio.
- Merger completion expected 1-2 months post second week June hearing.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for January to March 2026, 12 May 2026.
What is the future of J B Chemicals & Pharmaceuticals? What is changing in the business?
What is changing at J B Chemicals & Pharmaceuticals, from the latest results and calls: chronic portfolio mix shift, structural gross margin expansion, india market share gains, outperforming ipm consistently and torrent merger integration synergies.
- Chronic Portfolio Mix Shift, Structural Gross Margin Expansion. Chronic segment grew 19% vs industry 14% in FY26; trade-generics exit (7-8% of India sales) drove 400 basis points gross margin expansion to 70% in Q4, structural improvement, not seasonal. ⚠ estimate
- India Market Share Gains, Outperforming IPM Consistently. Fastest growing among top-25 IPM companies; 300-400 basis points volume growth advantage; 6 brands now in top-300 IPM. ⚠ estimate
- Torrent Merger Integration Synergies. Procurement synergies visible since April 2026; distribution network optimization underway; back-end consolidation and coverage expansion for chronic therapies expected post-merger completion. ⚠ estimate
- CDMO Business Recovery (Execution-Dependent). CDMO flat at ₹494 crore in FY26 vs 12-14% guide; management confirms customers and capacity are adequate, execution acceleration is the only constraint. ⚠ estimate
We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.
Our read after the January to March 2026 results, written 17 May 2026.
What could change the J B Chemicals & Pharmaceuticals story? What are the risks?
4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact.
The main risks
- Management Guidance Credibility, Systematic Pattern of Misses: 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact. ✓ fact
- Trade Generics Exit Depresses Reported Growth 3+ Quarters: ~7-8% of India sales (low-margin trade generics) discontinued in Q4; will depress reported India growth by 'a few percent' through January to March 2027 minimum per management. ✓ fact
- CDMO Execution Risk, Internal Process Development Bottleneck: CDMO execution delays are internal (team capability gap in process development, not capacity or customer), credibility lowest after missing guidance by 12-14pp in FY26. ✓ fact
- International Formulations, West Asia Geopolitical Uncertainty: International formulations down 9% in January to March 2026; container congestion in Middle East/Asia plus inventory rationalization; West Asia crisis timing 'anybody's guess' per management. ✓ fact
Our read after the January to March 2026 results, written 17 May 2026.
What to watch in J B Chemicals & Pharmaceuticals' next results?
When J B Chemicals & Pharmaceuticals reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: April to June 2026 India branded business organic growth rate - compare Q4 8% to Q1 results; management guided couple of quarters to double-digit return, so Q1 should inflect higher if operational reset normalizing; slowdown below 5-6% would signal headwinds exceed expectations.
Management raised each of these on the latest results call.
- April to June 2026 India branded business organic growth rate - compare Q4 8% to Q1 results; management guided couple of quarters to double-digit return, so Q1 should inflect higher if operational reset normalizing; slowdown below 5-6% would signal headwinds exceed expectations.
- Gross margin normalized run-rate guidance in Q1 results - management explicitly deferring FY27 full-year margin guidance to Q1 pending clean portfolio clarity; watch for steady-state operating margin indicating where trade-generics-free business settles and validating synergy assumptions.
- Merger completion announcement and post-close roadmap - hearing second week June with expected 1-2 month completion window; watch for announcement timing, first quantified synergy goals, and field force deployment plan for chronic product coverage expansion priority.
- CDMO Q1 revenue trajectory and development pipeline evidence - management identified execution not capacity as constraint; watch for Q1 new product launches from top five customers (P&G, Kenvue, Abnova, Reckitt) indicating execution acceleration delivering results.
Which stock lists is J B Chemicals & Pharmaceuticals on?
J B Chemicals & Pharmaceuticals is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.
Is J B Chemicals & Pharmaceuticals profitable?
J B Chemicals & Pharmaceuticals Ltd earned ₹101 Cr of net profit in the Mar 2026 quarter, −30.8% on the same quarter a year earlier. Full-year FY26 profit was ₹709 Cr. Over 10 years profit has grown 15.8% a year on average. The Mar 2026 quarter's profit is 11.2% of that quarter's revenue.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The same quarter a year earlier earned ₹146 Cr.
For the full year, FY26 profit was ₹709 Cr (+7.4% on the year before).
Why profit moved: revenue changed −4.7% on a year earlier and the margin moved −1.6 percentage points. Sales did the work, and the margin was about flat.
On average over the last four quarters, profit changed +6.1% and revenue +5.8%. Profit and revenue are moving at about the same pace.
How much revenue does J B Chemicals & Pharmaceuticals make, and is it growing?
J B Chemicals & Pharmaceuticals Ltd reported ₹904 Cr of revenue in the Mar 2026 quarter, −4.7% on the same quarter a year earlier. Over 10 years it has grown 13.1% a year on average. The last full year, FY26, came in at ₹4,148 Cr. The last four reported quarters add to ₹4,148 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. JB Pharma has sustained 200-400 bps outperformance of IPM growth for multiple years. Q1 FY26: 13% vs 9% market (+400bps); Q2 FY26: 12% domestic vs 8% market; Q3 FY26: domestic grew 10% outperforming IPM. Six brands in top-300 IPM, three brands in top-100. Volume growth consistently 4-5% vs IPM 0.3-1%. The merged Torrent entity is expected to add coverage in chronic therapy areas where JB brands have gaps, potentially accelerating share gains.
FY26 revenue was ₹4,148 Cr, +5.9% on the year before.
Recent pace: the last four quarters grew +5.8% on average, against 13.1% a year over the longer run, so this year is growing slower than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +5.9%, against +9.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +7.4%, against +13.2% a year (rolling over).
Watch next
- Metric
- India Market Share Gains, Outperforming IPM Consistently
- Threshold
- Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum?
- Which result
- the next result
How much of every ₹100 of sales does J B Chemicals & Pharmaceuticals keep?
J B Chemicals & Pharmaceuticals Ltd's operating margin was 22.2% in the Mar 2026 quarter, 1.6 percentage points lower than the same quarter a year ago. Across 13 years it has been between 14.5% and 27.4%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. JB Pharma has been systematically pivoting its India business toward higher-margin chronic therapies (cardiology, ophthalmology, CNS) since the Novartis ophthal portfolio acquisition. FY26 India branded grew 11% vs 10% IPM with chronic +19% vs +14% industry. The Q4 discontinuation of the trade-generics business (~7-8% of India sales running at zero margin per Torrent's commentary) eliminated the biggest margin drag, lifting gross margin 400bps to 70%. Key franchises: Rosuvastatin crossed Rs 100 Cr MAT, Sporolac grew from Rs 70 Cr (June 2022) to Rs 146 Cr (June 2025), Azmarda at Rs 75 Cr in cardiology heart failure. The chronic thesis is durable and margin-accretive.
Why the margin moved: operating margin changed −1.6 percentage points on the year while gross margin changed +3.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged.
Watch next
- Metric
- Chronic Portfolio Mix Shift, Structural Gross Margin…
- Threshold
- Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum?
- Which result
- the next result
Is J B Chemicals & Pharmaceuticals' profit turning into cash?
Over the last 3 years, 125% of J B Chemicals & Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹704 Cr of operating cash against ₹709 Cr of profit. After ₹83.0 Cr of spending on assets, ₹621 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 125% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.
What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.
Where does J B Chemicals & Pharmaceuticals' cash go?
J B Chemicals & Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 151 days in FY26, down from 153 days in FY21. It spent ₹308 Cr on assets over the last 3 years. Customers take 69 days to pay, and stock sits for 192 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹4,148 Cr, each day of that cycle ties up about ₹11.4 Cr, so roughly ₹1,716 Cr is tied up in the business at any time.
FY26: customers took 69 days to pay and stock sat for 192 days, about 6.3 months of sales sitting as stock, for a full cycle of 151 days, shorter than FY21's 153.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 192 days. Customers pay about 69 days after that. Suppliers are paid at 110 days. Together that makes the 151-day cycle.
Spending on assets: ₹308 Cr over the last 3 years, against ₹491 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹74.0 Cr (FY26): assets paid for that are not earning yet.
In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.
What is J B Chemicals & Pharmaceuticals' P/E ratio, and how does it compare with its own history?
J B Chemicals & Pharmaceuticals Ltd's P/E is 53.2×, about the highest it has ever been. Its usual P/E (the middle reading) is 27.6×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why this happened. JB Pharma's debt-free status since debt repayment enables treasury income that compounds PAT growth. Other income grew from Rs 8 Cr to Rs 18 Cr YoY in Q3 FY26 purely from surplus cash deployment. With net cash at Rs 1,200 Cr post-Q4, this ~Rs 70-80 Cr annualized contribution is a structural PAT support. The Rs 9.3/share dividend recommendation signals continued return discipline.
Why the multiple is where it is: over the past year earnings per share moved +6.6% while the price moved +45.6%. The price did better than earnings, which pushed the multiple up within its own range.
Where the price move came from: over 3 years the price moved +23.3% a year; about +19.5% a year came from earnings growth and about +3.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
Watch next
- Metric
- Treasury Income Compounding from Debt-Free Balance Sheet
- Threshold
- Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum?
- Which result
- the next result
What growth does the J B Chemicals & Pharmaceuticals share price assume?
Worked out from its price on 13 June 2026, J B Chemicals & Pharmaceuticals Ltd's share price assumed profit growth of about 25.8% a year. Over the past 10 years its profit actually grew 15.8% a year. Today its P/E is 53.2×, higher than 98% of its own last 10 years.
This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.
This is a one-day reading, taken on 13 June 2026. Every other number on this page, the multiple included, uses the latest price as of 16 July 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.
Is the J B Chemicals & Pharmaceuticals business getting better or worse?
J B Chemicals & Pharmaceuticals Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 25.1% (year to Mar 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: steady growth with healthy returns is how a business compounds over time.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +5.9% | +9.6% | +15.2% | +13.1% |
| Profit | +7.4% | +20.0% | +9.6% | +15.8% |
| EPS | +4.3% | +18.6% | +8.8% | +16.5% |
| Share price | +45.6% | +23.3% | +20.6% | +33.8% |
What is the J B Chemicals & Pharmaceuticals story, and has it been checked?
J B Chemicals & Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: fully expanded.
NOT YET CHECKED
Our read, 17 May 2026. A chronic-mix compounder hit by a Torrent-integration reset, the branded core is intact, but CDMO missed by 12-14pp and management guidance credibility is impaired.
From the numbers. FII stake-cutting since Dec 2024 peak of 14.64%. Cycle segment is FULLY EXPANDED…
From the price. Price stage 2, week 34, above its 200-day line, relative strength rising.
What is not proven yet. 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact.
The test written in advance. Management Guidance Credibility, Systematic Pattern of Misses. Measured by: Management Guidance Credibility, Systematic Pattern of Misses Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum? by the next result.
The test written in advance. Trade Generics Exit Depresses Reported Growth 3+ Quarters. Measured by: Trade Generics Exit Depresses Reported Growth 3+ Quarters Organic branded India growth (ex-trade generics), must track separately from reported topline by the next result.
What the company does. India branded grew 11% vs 10% IPM in FY26; chronic segment +19% vs industry +14%; 400bps gross margin expansion in Q4 to 70% from trade-generics exit, the underlying franchise is healthy. CDMO finished FY26 flat at Rs 494 Cr vs explicit 12-14% growth guidance held across two prior calls; execution delays surfaced for the first time post-acquisition, the highest-multiple segment has now missed guidance 3 consecutive times in 4 calls. FII stake-cutting;.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters |
|---|---|---|
| Chronic Portfolio Mix Shift, Structural… | HIGH | Chronic segment grew 19% vs industry 14% in FY26; trade-generics exit (7-8% of India sales) drove 400bps gross margin expansion… |
| India Market Share Gains, Outperforming… | MEDIUM HIGH | Fastest growing among top-25 IPM companies; 300-400bps volume growth advantage; 6 brands now in top-300 IPM. |
| Torrent Merger Integration Synergies | MEDIUM | Procurement synergies visible since April 2026; distribution network optimization underway; back-end consolidation and coverage… |
| CDMO Business Recovery (Execution-Dependent) | MEDIUM | CDMO flat at Rs 494 Cr in FY26 vs 12-14% guide; management confirms customers and capacity are adequate, execution acceleration… |
| Treasury Income Compounding from Debt-Free… | LOW MEDIUM | Other income Rs 18 Cr in Q3 FY26 (vs Rs 8 Cr prior year) from treasury income on net cash Rs 939 Cr (Sep 2025) rising to Rs… |
Everything further down this page is evidence for or against these.
FY26-Q1FY26-Q4
- 1 · Operating leveragequiet
- 2 · Value-added mixbuilding
- 3 · Management changebuilding
- 4 · Paying down debtquiet
- 5 · Regulatory approvalbuilding
- 6 · Order-book winsquiet
- 7 · Consolidationquiet
- 8 · Demerger or value unlockbuilding
- 9 · Buybackquiet
- 10 · New geographiesquiet
- 11 · More business from existing customersquiet
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsbuilding
- 16 · Asset qualityquiet
Lever 2 · Value-added mix: building. Chronic segment grew 19% vs industry 14% in FY26; trade-generics exit (7-8% of India sales) drove 400bps gross margin expansion to 70% in Q4, structural improvement, not seasonal. What proves it keeps working: Chronic Portfolio Mix Shift, Structural Gross Margin Expansion. It stops working if Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum?
Lever 15 · Market-share gains: building. Fastest growing among top-25 IPM companies; 300-400bps volume growth advantage; 6 brands now in top-300 IPM. What proves it keeps working: India Market Share Gains, Outperforming IPM Consistently.
Lever 5 · Regulatory approval: building. Procurement synergies visible since April 2026; distribution network optimization underway; back-end consolidation and coverage expansion for chronic therapies expected post-merger completion. What proves it keeps working: Torrent Merger Integration Synergies.
Lever 3 · Management change: building. CDMO flat at Rs 494 Cr in FY26 vs 12-14% guide; management confirms customers and capacity are adequate, execution acceleration is the only constraint. What proves it keeps working: CDMO Business Recovery (Execution-Dependent).
Sources: our stock research file (17 May 2026) · quarterly results through Mar 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
| Section | Where it is now | The one thing to watch next |
|---|---|---|
| Margin | 22% | Chronic Portfolio Mix Shift, Structural Gross Margin… |
| Revenue | ₹904 Cr | India Market Share Gains, Outperforming IPM Consistently |
| Safety | see the section | Torrent Merger Integration Synergies |
| Ownership | see the section | CDMO Business Recovery (Execution-Dependent) |
Did J B Chemicals & Pharmaceuticals management deliver what it promised?
What J B Chemicals & Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
CDMO FY26 Annual Growth Guidance Missed · 12 May 2026. Both prior calls maintained explicit 12-14% FY26 CDMO growth guidance, with the Nov 2025 call additionally affirming a strong H2 FY26 order book and robust pipeline. The May 2026 call reveals CDMO finished the full year flat at 494 crores, approximately 12-14 percentage points below the guided growth rate. Execution delays in product delivery are now surfaced for the first time as a structural challenge, a risk that went entirely unmentioned in both prior calls.
India Domestic FY26 Growth Guidance Missed · 12 May 2026. Both prior calls maintained explicit 12-14% domestic business growth guidance for FY26, with the Nov 2025 management reaffirming it directly in response to an analyst question. The May 2026 call reports full-year India business growth of only 9% overall and 11% for branded, attributing the shortfall to trade generics rationalization - a business line contributing 7-8% of India revenue that was never flagged as a risk to the 12-14% guidance in either prior call.
International Formulations H2 FY26 Recovery Guidance Contradicted · 12 May 2026. The Nov 2025 call explicitly guided for high single-digit H2 FY26 growth in ROW markets and a South Africa bounce-back, citing a strong order book. Instead, Q4 FY26 international formulations declined 9% and full-year growth was only 2%. The May 2026 call attributes the Q4 decline to an operational reset under Torrent and container shipping disruptions - factors entirely absent from the Nov 2025 recovery narrative.
CDMO FY27 Quarterly Run Rate Goal Not Reaffirmed and Execution Delays Newly Surfaced · 12 May 2026. The Jul 2025 call committed to a specific FY27 quarterly CDMO run rate of INR140-150 crore, implying roughly 13-21% growth from the now-flat FY26 base, and Nov 2025 closing remarks continued to support mid-teens CDMO growth going forward. The May 2026 call, the first post-acquisition opportunity to address FY27 CDMO outlook, provides only vague positive momentum language and newly surfaces structural execution delays, without acknowledging or updating the prior specific quarterly run rate goal.
Every quote above is taken word for word from the company’s own earnings calls.
What is J B Chemicals & Pharmaceuticals management's track record?
J B Chemicals & Pharmaceuticals (JB Pharma) demonstrates a robust track record of meeting or exceeding management guidance. For FY25, the company delivered 12% revenue growth (₹3,918 crore) and 14% domestic formulation growth, hitting the upper end of its 12-14% guidance. Despite a temporary slowdown in the CDMO segment during H1 FY25, management's guidance for a H2 recovery was validated by an 18.3% on a year earlier bounce in January to March 2025. In FY26, the company has maintained its guided operating margin corridor of 27-29%, reporting 28.7% in October to December 2025.
Regulatory and governance record
J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is largely clean of major regulatory red flags, with no active SEBI bans, CBI investigations, or fraud chargesheets found as of April 2026. The most significant recent regulatory event is a GST penalty of ₹80.81 lakh (not ₹80.81 crore as misreported by some aggregators) issued by the State Tax Officer, Chennai, on March 18, 2026. This penalty, under Section 74 of the GST Act, relates to tax liability differences for FY 2019-20. The company is appealing the order and expects no material financial impact. Additionally, the company processed a promoter reclassification request for Tau Investment Holdings Pte. Ltd in January 2026 and saw the resignation of three senior executives in March 2026, which appear to be routine corporate transitions.
Checked 20 April 2026.
How much does J B Chemicals & Pharmaceuticals earn on its capital?
J B Chemicals & Pharmaceuticals Ltd earned a ROCE of 25% in FY26. That is up from a low of 11% in FY18. Its return on capital used (ROIC) is 10.2 percentage points above its cost of capital, so growth here adds value, not just size.
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
It comes from a 17.1% net margin and 0.84× asset turnover (sales divided by assets).
Why the return is what it is (FY26): a 17.1% net margin × 0.84× asset turnover × 1.19× leverage (assets divided by equity) ≈ 17.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 22.2% − 12.0% = +10.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
Does J B Chemicals & Pharmaceuticals have too much debt?
J B Chemicals & Pharmaceuticals Ltd has total debt of ₹4.0 Cr against shareholder equity of ₹4,159 Cr as of Mar 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.00 in FY26.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
So the returns on this page come from the business, not from borrowed money.
What is the J B Chemicals & Pharmaceuticals shareholding pattern?
Promoters cut their stake in J B Chemicals & Pharmaceuticals Ltd by 5.0 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 48.8% of the company. Foreign institutions moved +4.2 points over the same period, to 16.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Why this happened. CDMO has top-5 originator customers (P&G, Kenvue, Abnova, Reckitt, unnamed fifth) with signed contracts in place. The execution bottleneck is in process development capability, management stated under analyst pressure that 'customers and capacities are present; it is just execution that needs to be addressed.' FY27 goal of Rs 140-150 Cr quarterly (guided July 2025) was abandoned without update, but management expressed confidence in positive momentum on a 12-month basis. If execution genuinely improves (team expansion, faster delivery), CDMO could accelerate from the flat FY26 base. Not underwritten until Q1 FY27 actuals show recovery.
Over the last two years: Promoters: −5.0 points over 8 quarters, to 48.8%; Foreign institutions: +4.2 points over 8 quarters, to 16.3%; Domestic institutions: +3.8 points over 8 quarters, to 21.4%.
Why the owners changed: promoters drove it (−5.0 points), with the other side taken by foreign institutions (+4.2 points). They reduced their stake.
Watch next
- Metric
- CDMO Business Recovery (Execution-Dependent)
- Threshold
- Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum?
- Which result
- the next result
How far is J B Chemicals & Pharmaceuticals from balance-sheet trouble?
For J B Chemicals & Pharmaceuticals Ltd, the Z-score is 23.55. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
Why this happened. Torrent acquired KKR's 46.39% stake for Rs 11,917 Cr (closed January 21, 2026), with merger hearing scheduled second week June 2026 and completion expected 1-2 months thereafter. Synergy levers: (1) procurement advantages visible since April, (2) distribution network optimization, (3) back-end function consolidation, (4) field force coverage expansion for JB's chronic brands through Torrent's larger network. Revenue synergies require merger completion before they materialize. Rs 400-450 Cr total synergy estimate over 2-3 years per Torrent's Q3 FY26 commentary.
Why it matters: a Z-score of 23.55 is well clear of the danger zone, so the balance sheet is not the risk here.
Watch next
- Metric
- Torrent Merger Integration Synergies
- Threshold
- Q1 FY27, does India branded return to double-digit as guided? Does CDMO show positive momentum?
- Which result
- the next result
How does J B Chemicals & Pharmaceuticals rank in its industry?
45.8 out of 100, rank 29 of 44 in Pharma - Formulators, with 59% of the evidence available.
J B Chemicals & Pharmaceuticals Ltd scores 45.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 29. Some evidence is missing, so the score is pulled toward the middle on purpose.
The three scored parts add up to the total exactly: 16.4 + 22.1 + 7.3 = 45.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is J B Chemicals & Pharmaceuticals compared with?
J B Chemicals & Pharmaceuticals ranks 29 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 45.8 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
- 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals Ltd this pageJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
How the score adds up
Growth & earnings 16.4/43.75 · Revenue 5.9% · Profit 7.4% · Operating margin change -2 points · 56% evidenceCapital efficiency 22.1/31.25 · ROCE 25.4% (year to Mar 2026) · Operating margin 22.2% · 75% evidenceValuation 7.3/25 · P/E 53.2× · PEG 1.97 · 100% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 16.4 + 22.1 + 7.3 = 45.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. - 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to J B Chemicals & Pharmaceuticals in size?
J B Chemicals & Pharmaceuticals is the 15th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Ipca Laboratories, Emcure Pharmaceuticals and Ajanta Pharma. Just below it: Wockhardt, Rubicon Research and Alembic Pharmaceuticals.
Pharma - Formulators companies close in size
- Ipca Laboratories Ltd ₹47,039 crore
- Emcure Pharmaceuticals Ltd ₹44,294 crore
- Ajanta Pharma Ltd ₹40,910 crore
- J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore
- Wockhardt Ltd ₹32,934 crore
- Rubicon Research Ltd ₹27,451 crore
- Alembic Pharmaceuticals Ltd ₹20,528 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Anand Rathi Wealth Ltd ₹39,437 crore · Finance - Capital Markets - Wealth Management
- Rail Vikas Nigam Ltd ₹39,407 crore · Infra - Construction & Contracting
- J B Chemicals & Pharmaceuticals Ltd ₹38,677 crore
- Narayana Hrudayalaya Ltd ₹38,650 crore · Hospitals
- Global Health Ltd ₹38,627 crore · Hospitals
What else do people ask about J B Chemicals & Pharmaceuticals?
What were J B Chemicals & Pharmaceuticals's latest quarterly results?
J B Chemicals & Pharmaceuticals Ltd reported revenue of ₹904 Cr and net profit of ₹101 Cr for the Mar 2026 quarter. Revenue fell 4.7% and profit fell 30.8% compared with a year earlier. Earnings per share were ₹6.31 (as of 16 July 2026).
What is J B Chemicals & Pharmaceuticals's market cap?
J B Chemicals & Pharmaceuticals Ltd's market capitalisation is ₹38,677 Cr at a share price of ₹2,408.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 16 July 2026).
How is J B Chemicals & Pharmaceuticals performing?
J B Chemicals & Pharmaceuticals Ltd's share price has been rising for 34 weeks. In its latest quarter, revenue fell 4.7% and profit fell 30.8% compared with a year earlier.
Over the past 13 weeks it has done better than the NIFTY 500, for 9 weeks running (as of 16 July 2026).
Will J B Chemicals & Pharmaceuticals's share price go up?
This page does not forecast J B Chemicals & Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹2,408.90, and it has been rising for 34 weeks. Its P/E of 53.2× is higher than 98% of its own last 10 years (as of 16 July 2026).
Where is J B Chemicals & Pharmaceuticals in its business cycle?
J B Chemicals & Pharmaceuticals Ltd's FY26 operating margin was 26.7%, against a 13-year range of 14.5% to 27.4%. The latest quarter was 22.2%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 16 July 2026).
What could break the J B Chemicals & Pharmaceuticals story?
The main question: the share price moved +45.6% in a year while earnings per share (last four quarters) moved +6.6%. The difference came from the market paying a higher multiple.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 16 July 2026).
Is J B Chemicals & Pharmaceuticals a stock worth studying right now?
What the numbers show: J B Chemicals & Pharmaceuticals Ltd's share price has risen faster than its earnings: +45.6% in a year, against +6.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 16 July 2026).
Is there a J B Chemicals & Pharmaceuticals share price forecast for 2026?
What management itself guided: India branded business return to double-digit or low-teens growth within couple of quarters.
What is changing at J B Chemicals & Pharmaceuticals, from the latest results and calls: chronic portfolio mix shift, structural gross margin expansion, india market share gains, outperforming ipm consistently and torrent merger integration synergies. What would change the story: 4 clear guidance misses across 4 calls: CDMO (flat vs 12-14%), domestic (9% vs 12-14%), international (Q4 -9% vs high-single H2 guide), CDMO FY27 run rate abandoned. Risks remain undisclosed until post-fact.
Where does this page get J B Chemicals & Pharmaceuticals' management information?
From J B Chemicals & Pharmaceuticals' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 16 July 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.